While Amicus will transfer the gene therapy portfolio’s R&D risk to Caritas, it retains a financial interest in many of the spinout’s programs. Pompe candidate AT-GAA accepted for FDA review.

The market for surgical heart valve replacement devices is projected to steadily decline, as newer, more innovative transcatheter techniques poach customers, according to a new report from Informa’s Meddevicetracker.

After three failures in quick succession, Merck needs to see a win in one of its many remaining Phase II trials.

Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.